Press contact:Sereydana OumTel.: +33 6 61 42 03 59E-mail: sereydana.oum@capgemini.com 82% of organizations now plan to increase investment in environmental sustainability in the next 12–18 months as a core future-proofing strategy The majority of organizations have been affected by climate disruption, yet executives are struggling to actively prepare for increased climate risks Paris, September 18, 2025 – The fourth edition of the Capgemini Research Institute’s report, “A world in balance 2025: Unlocking r ...

Core Viewpoint - Robex Resources Inc. has accelerated the expiry date of its 2024 Warrants due to a significant increase in its share price, reflecting positive developments in the company's operations and strategy [1][3][5] Summary by Sections Warrant Acceleration - The expiry date for the 2024 Warrants has been moved from June 27, 2026, to October 18, 2025, following an Acceleration Event where the volume weighted average trading price (VWAP) exceeded C$3.50 for ten consecutive trading days [1][2][3] - There are currently 57,759,921 2024 Warrants outstanding, and if all are exercised, the company expects to receive approximately C$147.3 million in gross proceeds [4] Company Strategy and Financial Outlook - The proceeds from the exercise of the 2024 Warrants will be utilized to fund exploration activities at the Kiniéro Gold Project, support the continued development of the Kiniero Mine, and provide flexibility for broader corporate initiatives in 2026 [5] - The first gold pour at the Kiniero project is scheduled for December 2025, with commercial production expected in Q1 2026, marking a transformative phase for the company [5]

Sampo plc, stock exchange release, 18 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 17 September 2025 On 17 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code) 5,8249.81AQEU 113,3529.81CEUX 32,1619.81TQEX 177,3199.81<td style="width: ...

IMPLEMENTATION OF A SHARE BUYBACK PROGRAM Saint-Ouen, 18 September 2025, 7:30 a.m. (CET) Nexity announces the implementation of a share buyback program, pursuant to the authorization granted at the Shareholders’ General Meeting held on 22 May 2025. The buyback mandate covers a maximum of 200,000 shares. These shares will be fully allocated to cover free share plans, particularly in the context of employee share ownership schemes. NEXITY, LIFE TOGETHERWith €3.5 billion in revenue in 2024, Nexity has a natio ...

Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most people living with spinal cord injury experience blood pressure instability, which represents a key unmet needToday’s concurrent publications provide clinical evidence for ARC-IM® Therapy ahead of the Company’s planned initiation of the Empower BP global pivotal trial later this year EINDHOVEN, The Netherlands, Sep ...

Core Viewpoint - 89bio, Inc. has entered into a merger agreement with Roche, with stockholders set to receive up to $20.50 per share, including a cash payment of $14.50 at closing and a contingent value right (CVR) of up to $6.00 per share, representing a total equity value of approximately $3.5 billion [1][3][6] Company Overview - 89bio is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardiometabolic diseases, currently in Phase 3 trials for its lead candidate, pegozafermin, targeting metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [9] Transaction Details - The merger agreement includes a tender offer for all outstanding shares at $14.50 per share, totaling an aggregate payment of $2.4 billion, with additional contingent payments based on specific milestones [3][4] - The CVR includes potential cash payments of $2.00 per share upon the first commercial sale of pegozafermin, $1.50 per share upon achieving annual net sales of at least $3.0 billion, and $2.50 per share for annual net sales of at least $4.0 billion [5] Strategic Implications - The merger aims to leverage Roche's global development and commercialization capabilities to enhance the potential benefits of pegozafermin for patients and unlock significant shareholder value [2] - Roche plans to integrate pegozafermin into its cardiovascular, renal, and metabolism portfolio, aiming to transform the standard of care for patients with moderate to severe MASH [2]

Core Insights - TGS has announced the PAMA Phase II 3D multi-client survey in the Equatorial Margin area offshore Brazil, expanding its coverage significantly in a highly prospective basin [1][2][4] - The survey will cover an additional 11,500 square kilometers, including blocks nominated for upcoming license rounds in 2026 and 2027 [2] - The project is supported by industry funding and utilizes advanced TGS GeoStreamer technology for high-quality data acquisition [2][4] Industry Context - The Pará-Maranhao Basin is recognized for its functioning deepwater petroleum system, attracting interest due to discoveries in neighboring countries like Guyana and Suriname [3] - TGS aims to leverage its advanced acquisition capabilities to provide substantial value for clients' exploration activities in the basin [4] - The ongoing Megabar extension multi-client project in the Barreirinhas Basin will see two Ramform Titan-class vessels active in the Equatorial Margin through the remainder of 2025 [4]

Core Viewpoint - Roche has entered into a definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for liver and cardiometabolic diseases, with the transaction expected to close in Q4 2025 [1][9]. Group 1: Acquisition Details - Roche will commence a tender offer to acquire all outstanding shares of 89bio at a price of US$14.50 per share in cash, plus a non-tradeable contingent value right (CVR) for milestone payments of up to US$6.00 per share, representing a total equity value of approximately US$2.4 billion and a total deal value of up to US$3.5 billion [5][7]. - The acquisition price represents a premium of approximately 52% to 89bio's 60-day volume-weighted average price (VWAP) as of September 17, 2025 [5][7]. - The merger agreement has been unanimously approved by the boards of both Roche and 89bio [5]. Group 2: Strategic Rationale - The acquisition supports Roche's strategy to enhance its portfolio in cardiovascular, renal, and metabolic diseases (CVRM), particularly targeting conditions associated with obesity and metabolic dysfunction [2][3]. - Pegozafermin, 89bio's lead candidate, is positioned to potentially offer best-in-disease efficacy for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH) patients, addressing critical unmet needs in this area [3][7]. - The distinct mechanism of action of pegozafermin may create synergies with Roche's existing CVRM portfolio, allowing for future combination development [2][3]. Group 3: Market Context - MASH is a serious and increasingly prevalent form of fatty liver disease, affecting an estimated 5-7% of the global adult population, with a significant association with obesity and type 2 diabetes [11]. - The condition can progress to severe complications, including cirrhosis and hepatocellular carcinoma, highlighting the need for effective treatment options [11]. Group 4: Employee Integration - Current employees of 89bio will join Roche's Pharmaceuticals Division as part of the acquisition [4].

AS LHV Group has decided the company’s Financial Calendar for the 2026 financial year. In 2026 LHV Group plans to disclose information and organise the Annual General Meeting of shareholders according to the following schedule: 10.02.2026Q4 2025 and unaudited full year results12.02.2026Disclosure of Financial Plan17.02.2026January results03.03.2026Audited results for 202517.03.2026February results25.03.2026Annual General Meeting09.04.2026Ex-dividend date (ex-date)<td style="width:160.34px;;text-align: cente ...

Press Release 42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030 (vs. 2022)25% reduction in Scope 3 GHG emissions by 2030 (vs. 2022) September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company’s alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels. EUROAPI commits to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissi ...